Financial Results, Clinical Study Updates, Clinical Trial Results, Business Spin-Offs, and New Joint Ventures - Analyst Notes on ARIAD, NewLink, Puma Biotechnology, Theravance, and Ohr Pharmaceutical

NEW YORK, March 12, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), NewLink Genetics Corporation (NASDAQ: NLNK), Puma Biotechnology, Inc. (NYSE: PBYI), Theravance, Inc. (NASDAQ: THRX), and Ohr Pharmaceutical, Inc. (NASDAQ: OHRP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

ARIAD Pharmaceuticals, Inc. Analyst Notes

On February 25, 2014, ARIAD Pharmaceuticals, Inc. (Ariad) reported Q4 2013 and full-year 2013 financial results. In Q4 2013, the Company's revenue totaled $8.4 million, compared with $74,000 in Q4 2012, while full-year 2013 revenue totaled $45.6 million, compared with $0.6 million in full year 2012. Q4 2013 net loss was $74.2 million, or $0.40 loss per diluted share, compared to a net loss of $60.5 million, or $0.36 loss per diluted share, in Q4 2012. Full-year 2013 net loss was $274.2 million, or $1.49 loss per diluted share, compared to a net loss of $220.9 million, or $1.34 loss per diluted share, for full-year 2012. "I am extremely pleased with the commercial and R&D progress we made in 2013, especially ending the year with Iclusig commercially available to refractory Philadelphia-positive leukemia patients in the United States. We are off to a strong start with our re-launch in the U.S. and are building momentum in Europe," said Harvey J. Berger, M.D., Chairman and CEO of ARIAD. The full analyst notes on ARIAD Pharmaceuticals, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03122014/ARIA/report.pdf

--

NewLink Genetics Corporation Analyst Notes

On March 7, 2014, NewLink Genetics Corporation (NewLink) announced that following the completion of first interim analysis of the Phase 3 IMPRESS clinical study of algenpantucel-L for patients with surgically resected pancreatic cancer, the Company's independent data safety monitoring committee recommends the continuation of the study. "As we have previously emphasized, continuation of this study was an anticipated outcome considering the high statistical threshold assigned to this first interim analysis under the special protocol assessment," said Dr. Charles Link, Chairman and CEO of NewLink. The full analyst notes on NewLink Genetics Corporation are available to download free of charge at:

http://www.AnalystsReview.com/03122014/NLNK/report.pdf

--

Puma Biotechnology, Inc. Analyst Notes

On March 5, 2014, Puma Biotechnology, Inc. (Puma Biotechnology) announced the schedule of an oral presentation to be held at the American Association for Cancer Research (AACR) Annual Meeting 2014, in which the results of the Phase II clinical trial of its investigational drug PB272 (neratinib) for the neoadjuvant treatment of breast cancer (I-SPY2 TRIAL) will be presented. The AACR event will be held on April 5-9, 2014 in San Diego, California, whereas the related presentation entitled "Neratinib plus Standard Neoadjuvant Therapy for High-Risk Breast Cancer: Efficacy Results from the I-SPY 2 TRIAL" will take place on April 7, 2014 between 10:30 a.m. and 12:30 p.m. PDT, during the session - "Clinical Trials Symposium: Biomarker Driven Clinical Trials." The full analyst notes on Puma Biotechnology, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03122014/PBYI/report.pdf

--

Theravance, Inc. Analyst Notes

On March 3, 2014, Theravance, Inc. (Theravance) announced that its intention to separate its businesses into two independent, publicly traded companies is expected to be completed in Q2 2014. Theravance also informed that it has entered into a series of agreements with Theravance Biopharma, Inc., and Glaxo Group Limited (GSK) clarifying how the companies will execute the spin-off and operate following the spin-off. "We continue to believe this separation will provide investors with the opportunity to unlock potential value from two different sets of assets, better align employee incentives and provide the opportunity for significant capital returns. Additionally, I am pleased that we recently entered into a series of agreements with GSK clarifying how the companies will operate following the separation and with the goal of bringing a portfolio of new respiratory products for the treatment of COPD and asthma to patients suffering from these debilitating diseases," said Rick E. Winningham, CEO of Theravance. The full analyst notes on Theravance, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03122014/THRX/report.pdf

--

Ohr Pharmaceutical, Inc. Analyst Notes

On March 3, 2014, Ohr Pharmaceutical, Inc. (Ohr) teamed up with Cold Spring Harbor Laboratory (CSHL) to announce the establishment of DepYmed Inc., a new joint venture to develop trodusquemine and related analogs. The Company informed that the new joint venture will be a private entity, initially with equal ownership by Ohr and CSHL. "Cold Spring Harbor Laboratory is a world class research center that has a track record of establishing successful commercial ventures in the biopharma space," said Irach Taraporewala, President and CEO of Ohr. "We are very pleased to be working with Dr. Nicholas Tonks who is one of the leading authorities on the protein tyrosine phosphatase (PTP) family of enzymes. Dr. Tonks discovered PTP1B, the primary target for trodusquemine. Setting up this joint venture is the optimal way to create shareholder value from this exciting asset and enable it to obtain the appropriate resources. At the same time, Ohr remains focused on the execution of our core strategy to develop novel ophthalmology products." The full analyst notes on Ohr Pharmaceutical, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03122014/OHRP/report.pdf

--

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES:

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review